Overview: NGS Cognitive Impairment Sequencing TestIntroduction: The NGS Cognitive Impairment Sequencing Test sequences genes to diagnose cognitive impairment, causing memory or thinking issues. Following 2023 AAN guidelines, it uses PCR for high specificity, supporting neurological screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in molecular pathology for patients with suspected cognitive impairment disorders.
Other Names: Cognitive Impairment NGS Assay, Cognitive Gene Panel.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: Cognitive impairment sequencing began in the 2000s with neurodegenerative research. NGS methods improved in the 2010s, enhancing diagnostic precision.
Purpose: Sequences genes to diagnose cognitive impairment, guides treatment, and evaluates patients with memory or thinking issues.
Test Parameters: 1. Cognitive Impairment Genes
Pretest Condition: No fasting required. Collect whole blood, buccal swab, or saliva. Report history of memory issues, confusion, or cognitive impairment symptoms.
Specimen: Whole Blood (EDTA, 2-5 mL), Buccal Swab (sterile swab, 1-2 swabs), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document memory issues, confusion, cognitive decline, or family history of cognitive impairment. Include current medications, especially cognitive enhancers.
Consent: Written consent required, detailing the tests purpose, cognitive impairment implications, and risks of sample collection.
Procedural Considerations: Uses next-generation sequencing to analyze cognitive impairment genes (e.g., APP, PSEN1). Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for cognitive impairment diagnosis.
Factors Affecting Result Accuracy: Low DNA yield or improper sample storage can affect results. Contamination may reduce specificity.
Clinical Significance: Identified mutations confirm cognitive impairment disorders, guiding supportive care or genetic counseling. Negative results may require cognitive testing.
Specialist Consultation: Consult a neurologist or geneticist for result interpretation and treatment planning.
Additional Supporting Tests: Cognitive testing, brain MRI, or CSF analysis to confirm cognitive impairment diagnosis.
Test Limitations: Not all cognitive impairment cases are genetic; clinical correlation is needed. Sample quality affects sensitivity.
References: AAN Cognitive Impairment Guidelines, 2023; Neurology, Petersen RC, 2022.
